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In this issue of the Journal, Harold Ellis provides his perspective on contemporary 
topics of medical discussion 50 years ago. At this stage, he was already a professor of 
surgery, and has since had a distinguished career as a clinician, academic, and 
renowned and inspirational educator. Here, we provide our perspectives looking 
back at the leading clinical articles from 1966, as two academic clinicians early in our 
careers. This is the recent history of many of the medical advances we now take for 
routine in our day-to-day practice, and highlights how far we have (or in several 
cases, have not) progressed over the past five decades. 
 
Therapeutics 
The 1960s witnessed considerable progress in the disciplines of transplant medicine, 
and oncology. The concept of immune-mediated transplant rejection had been 
established by Peter Medawar in 1943 (Gibson and Medawar, 1943), but the cellular 
mechanisms were only fully understood in 1966. A study of two patients who 
experienced hyperacute rejection of renal transplants suggested that this might be 
mediated by antibody, as these individuals had previously received multiple blood 
transfusions and their sera contained complement-fixing antibodies against donor 
kidney antigens (Kissmeyer-Nielsen et al., 1966). Rejection occurred within an hour, 
and microscopic examination excluded the cellular infiltrates that would have been 
expected with cell-mediated rejection. This observation was crucial for the 
refinement of strategies to allow transplant organ engraftment. The same year, one 
of the major complications of immunosuppression associated with transplant was 
also recognised: that cytomegalovirus could be acquired from transfused blood, and 
that this could then infect both donor and native organs (Kaariainen et al., 1966). 
There were life-saving advances of comparable magnitude in the 
development of chemotherapeutic regimens, particularly for haematological 
malignancies. Many of these agents remain part of the standard of care today 
(Kennedy and Yarbro, 1966; Stutzman et al., 1966). The utility of antimetabolites 
beyond cancer medicine, for immune-mediated disorders, was also beginning to 
emerge, with the first formal case series describing deployment of azathioprine in 
ulcerative colitis (Bowen et al., 1966). Nonetheless, it has only been over the last 10 
years that we have begun to master the delicate balance between efficacy and 
toxicity of this agent, with assays to measure thiopurine methyltransferase activity, 
thioguanine nucleotides and toxic metabolites (de Wit et al., 2013).  
Among the more every day examples of therapeutic advances were the 
development of allopurinol as a preventative for gout (Bartels, 1966), and heparin 
for prophylaxis and treatment of venous thromboembolic disease (described in 
depth in Harold Ellis’s commentary). In the cardiology world the first demand 
pacemakers were implanted, and scanning through the letters pages of JAMA there 
was a flurry of correspondence on how to manage patients with difficult venous 
access during cardiac arrests. Many contributors highlighted their own anecdotal 
success using the intraosseous route, a technique that has only recently found its 
way into routine guidelines.  
 
Toxicology 
Although paracetamol was first discovered in 1877, its use was initially superseded 
by the introduction of aspirin by Bayer. It was only reintroduced into the market at 
scale during the 1950s, when the risks of Reye’s syndrome in children became 
apparent. Just over a decade later, the first cases of overdose and its impact on the 
liver were published in the BMJ (Davidson and Eastham, 1966). Paracetamol remains 
the leading cause of drug overdose, and acute liver failure, in resource-rich countries 
today. This paper paved the route for the mechanistic understanding of its 
metabolism, including characterisation of N-acetyl-p-benzoquinone imine (NAPQI), 
and strategies to detoxify this through restoring glutathione. That this was a major 
advance is reflected by the fact that treatment protocols for managing overdose 
have barely changed since the 1970s. It is only in the past few years that there has 
been a substantial re-examination of this field with concerted efforts to identify 
novel biomarkers that enhance risk-stratification, and abbreviated individualised 
treatment protocols (Bateman et al, 2014).  
 The epidemiology of poisoning was also reshaping. There was an increase in 
accidental deaths in children due to wider access to chemical pesticides, a rise in 
both accidental and non-accidental overdoses with sedatives and tranquilizers, but a 
reduction in completed suicides due to gas inhalation (attributable to conversion of 
the cooking supply to non-toxic natural gas).  
 
New diseases, new mechanisms  
A number of conditions now standard in basic primers of medicine were first 
described or consolidated in the 1960s. Jerome Conn had recently proposed a 
syndrome of secondary hypertension caused by aldosterone-secreting adrenal 
tumours. He amalgamated his cases in a report in JAMA in which he suggested that 
this was relatively common, and that affected individuals had a cluster of four 
features: hypertension, hypokalaemia, aldosterone overproduction, and suppressed 
renin (Conn et al., 1966).  
The first recognition of an association between dermatitis herpetiformis and 
coeliac disease was a triumph of observational medicine. The authors embarked 
upon their study after appreciating that several other dermatoses were linked with 
gastrointestinal manifestations (Marks et al, 1966). This also established the 
importance of avoiding provoking food antigens in the management of dermatitis 
herpetiformis. 
 Although a descriptive association between alveolitis and contact with 
pigeons had already been identified, a paper in the Lancet extended the observation 
to include budgerigars, and prove that sensitivity arose to antigens present in 
excrement from both species (Hargreave et al, 1966). By performing both cutaneous 
and aerosol challenge, as well as demonstrating serum reactivity, this provided the 
causal basis and rational avoidance strategy to limit disease progression.  
Chronic Granulomatous Disease (CGD) is a primary immunodeficiency first 
described in 1957, but it was not until 1966 that neutrophils from these patients 
were demonstrated to have lost the ability to eradicate intracellular pathogens 
(Holmes et al., 1966). This seminal observation led to subsequent identification of 
the molecular mechanisms responsible for the respiratory burst, which underlies 
much of our current understanding of how the innate immune system kills bacteria.  
Finally, a unique and particularly exciting debate took place regarding the 
medical implications of manned space travel. Although both the USSR and US had 
sent astronauts on orbital spaceflights, the current discussion anticipated the Apollo 
moon landing three years later.  
 
Diagnostics and prognostication 
Considerable effort over the past 50 years has gone into elucidation of risk factors 
that identify individuals at risk of ischaemic heart disease. Notwithstanding the 
tremendous amount of work that has since gone into refinement of these tools, it is 
noteworthy that a prospective study of bus drivers in 1966 concluded that four 
parameters were predictive: blood pressure, serum lipids, smoking, and obesity 
(Morris et al., 1966). In the same year, reports emerged that testing serum creatine 
phosphokinase in patients presenting with chest pain halved the number of missed 
myocardial infarctions. Emphasis was still placed on the value of clinical examination 
skills, such as the prognostic importance of fundoscopy in hypertension (Breslin et 
al., 1966), although there was already evidence that the autopsy was in decline 
(Wilson, 1966). 
Reminiscent of comments recently emanating from the Department of 
Health, JAMA published a symposium on the new role of computers in medicine, 
including as aids to diagnosis. Their advent was likened to the agricultural and 
industrial revolutions (Ledley, 1966), although it would appear that the intervening 
50 years has not been sufficient to replace the clinician at the bedside. 
 
Service organisation 
On July 1, 1966, the majority of American Hospitals qualified for the new Medicare 
programme, providing health insurance to those aged 65 or over, irrespective of 
race, colour or national origin (Stewart, 1966). Correspondence over subsequent 
months highlighted some of the teething issues with the programme, but 
nonetheless this was a major contributor to both socialised healthcare and racial 
desegregation in medical facilities. 
 Even in 1966, articles were discussing the emergency department 
“problem”, recognising that “for many years, the emergency service has been the 
most neglected and often the weakest department in the hospital. Administrators 
look on it as a drain of resources; physicians debate the proper staffing. Increased 
used, however, has created pressures on the hospital and medical staff to provide a 
more adequate service” (1966). The same authors noted that “the number of 
emergency department visits has increased faster than either hospital inpatient 
admissions or outpatient visits, and indications are that these trends will continue at 
a growing rate.” Plus ça change, plus c’est la meme chose. 
 
Attitudes 
An important topic of discussion in both the British and American literature was 
medical abortion, with the British Abortion Act passed the following year. 
“Therapeutic” abortion was already on the radar, particularly in the aftermath of the 
thalidomide disaster, with a frequent view that “a doctor will, in all likelihood, refuse 
even to discuss the possibility of abortion and will usually offer only reassurances” 
(Niswander et al., 1966). 
 A picture of how other attitudes have evolved can be gleaned from the 
titles of a number of articles, a selection of which include: “Prevention of VD in the 
sexually promiscuous”; “Psychotherapy of the mentally retarded”; “The incidence of 
carcinoma of the prostate in Jews and Gentiles”; and “The theatre and the 
homosexual”. While some might bemoan the march of political correctness, in 
reality the medical profession has discarded many of its prejudices and made 
substantial progress towards embracing historically more vulnerable patients and 
their individual health needs. 
 A look back at the literature highlights how much research ethics have also 
evolved. For example, in one study, the aim was to determine whether a single drink 
was sufficient to provoke a relapse in individuals with alcohol dependence. Patients 
were recruited from an addiction unit and asked to participate in a trial investigating 
means to maintain their abstinence. They were unaware that the “vitamin” cocktail 
they received contained alcohol (Merry, 1966). Controls on use of animals for 
medical research were also more lax than today, although these too were starting to 
come under increasing political scrutiny (Visscher, 1966). 
 
Medical publishing 
One of the most striking qualities of articles from 1966 is that brevity was frequently 
the norm, both of their content and authorship. This provides a marked contrast to 
many manuscripts submitted today, with their ever-expanding cohorts of authors 
and reams of Supplementary data, often reflecting the increased technology 
available and subspecialist expertise required for its engagement. One illuminating 
feature, which we do not see enough of today, is that JAMA ran a regular article 
series called “Negative results”, providing a home for manuscripts that disprove 
important hypotheses. Such a resource, in a high impact factor journal, might go 
some way to reducing the publication biases that still plague evidence-based 
medicine. 
 Finally, reminiscent of the recent debate surrounding open access publishing, 
one letter in the 1966 correspondence pages lamented the economic impact of the 
newly available photocopiers on journals reliant on reprint sales for economic 
support.  
 
Epilogue 
This commentary can only provide a taster of the themes arising in the medical 
literature of 50 years ago, but for the more junior clinicians this is an important 
retrospective into how many of the practices we take for granted were innovated. 
Also informative, though sadly out of scope for this viewpoint, are the much greater 
number of studies describing interventions that have not stood the test of time. It is 
likely that the majority of trials published in high-ranking journals today will share 
the same fate. Finally, it is salutary to be aware of the areas where the medical 
profession has struggled to make progress. Without a radical rethink in the ways we 
structure, deliver and consume healthcare, there is a real risk that, in another 50 
years’ time, A&E will still be a problem. 
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